The North America Cancer Gene Therapy Market would witness market growth of 19.6% CAGR during the forecast period (2022-2028).
Cancer gene therapy is a strategy for treating cancer that involves inserting therapeutic DNA into the patient's gene. Cancer gene therapy has grown in popularity as a result of its high success rate in preclinical and clinical trials. For cancer gene therapy, a method in which the mutant gene is replaced with a healthy gene or the inactivation of the gene whose function is improper are two examples. Cancer gene therapy is a type of cancer treatment in which a faulty gene (which causes cancer) is transferred or replaced with a healthy gene utilizing genetically modified vectors such as viruses. This method can be utilized for both illness prevention and treatment. Oncolytic virotherapy, gene transfer, and gene-induced immunotherapy are the most regularly utilized strategies for cancer gene therapy treatment.
Some of the prominent trends in the regional market are increased government initiatives, rising economies, and improvements in healthcare infrastructure. In addition, increasing R&D investment, a big pool of patients, and expanding government financing are some of the primary driving reasons for the cancer gene therapy industry in developed countries. The United States has a large part of the market in North America. The increasing number of government funding, developments in gene therapy research and development, and the increased incidence of target diseases would help the regional market.
For example, according to the 2020 Spinal Muscular Atrophy Foundation, spinal muscular atrophy (SMA) affects between 10,000 and 25,000 children and adults in the United States, making it one of the most frequent uncommon diseases. According to the same source, one in 40 to one in 50 people (about 6 million Americans) carries the SMA gene. As a result, the figures show that gene therapy is becoming more popular in the United States.
The US market dominated the North America Cancer Gene Therapy Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,297.3 million by 2028. The Canada market is experiencing a CAGR of 22.3% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 21.2% during (2022 - 2028).
Based on Therapy, the market is segmented into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. Based on End User, the market is segmented into Hospitals, Diagnostic centers and Research Institutes. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Cancer Gene Therapy Market is Estimated to reach $5 Billion by 2028, at a CAGR of 21.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, GlaxoSmithKline PLC (GSK), Amgen, Inc., Bristol Myers, Squibb Company, Karyopharm Therapeutics, Inc., Gilead Sciences, Inc., Adaptimmune Limited, Genelux Corporation, and Sarepta Therapeutics, Inc
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Gene Induced Immunotherapy
- Oncolytic Virotherapy, and
- Gene Transfer
By End User
- Hospitals
- Diagnostic centers
- Research Institutes
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- GlaxoSmithKline PLC (GSK)
- Amgen, Inc.
- Bristol Myers Squibb Company
- Karyopharm Therapeutics, Inc.
- Gilead Sciences, Inc.
- Adaptimmune Limited
- Genelux Corporation
- Sarepta Therapeutics, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Cancer Gene Therapy Market, by Therapy
1.4.2 North America Cancer Gene Therapy Market, by End User
1.4.3 North America Cancer Gene Therapy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Cancer Gene Therapy Market by Therapy
3.1 North America Gene Induced Immunotherapy Market by Country
3.2 North America Oncolytic Virotherapy Market by Country
3.3 North America Gene Transfer Market by Country
Chapter 4. North America Cancer Gene Therapy Market by End User
4.1 North America Hospitals Market by Country
4.2 North America Diagnostic centers Market by Country
4.3 North America Research Institutes Market by Country
Chapter 5. North America Cancer Gene Therapy Market by Country
5.1 US Cancer Gene Therapy Market
5.1.1 US Cancer Gene Therapy Market by Therapy
5.1.2 US Cancer Gene Therapy Market by End User
5.2 Canada Cancer Gene Therapy Market
5.2.1 Canada Cancer Gene Therapy Market by Therapy
5.2.2 Canada Cancer Gene Therapy Market by End User
5.3 Mexico Cancer Gene Therapy Market
5.3.1 Mexico Cancer Gene Therapy Market by Therapy
5.3.2 Mexico Cancer Gene Therapy Market by End User
5.4 Rest of North America Cancer Gene Therapy Market
5.4.1 Rest of North America Cancer Gene Therapy Market by Therapy
5.4.2 Rest of North America Cancer Gene Therapy Market by End User
Chapter 6. Company Profiles
6.1 Novartis AG
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 GlaxoSmithKline PLC (GSK)
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Amgen, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expenses
6.4 Bristol Myers Squibb Company
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.5 Karyopharm Therapeutics, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expense
6.6 Gilead Sciences, Inc.
6.6.1 Company overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Adaptimmune Limited
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.8 Genelux Corporation
6.8.1 Company Overview
6.9 Sarepta Therapeutics, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Research & Development Expenses
TABLE 1 North America Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 2 North America Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 3 North America Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 4 North America Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 5 North America Gene Induced Immunotherapy Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Gene Induced Immunotherapy Market by Country, 2022 - 2028, USD Million
TABLE 7 North America Oncolytic Virotherapy Market by Country, 2018 - 2021, USD Million
TABLE 8 North America Oncolytic Virotherapy Market by Country, 2022 - 2028, USD Million
TABLE 9 North America Gene Transfer Market by Country, 2018 - 2021, USD Million
TABLE 10 North America Gene Transfer Market by Country, 2022 - 2028, USD Million
TABLE 11 North America Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 12 North America Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 13 North America Hospitals Market by Country, 2018 - 2021, USD Million
TABLE 14 North America Hospitals Market by Country, 2022 - 2028, USD Million
TABLE 15 North America Diagnostic centers Market by Country, 2018 - 2021, USD Million
TABLE 16 North America Diagnostic centers Market by Country, 2022 - 2028, USD Million
TABLE 17 North America Research Institutes Market by Country, 2018 - 2021, USD Million
TABLE 18 North America Research Institutes Market by Country, 2022 - 2028, USD Million
TABLE 19 North America Cancer Gene Therapy Market by Country, 2018 - 2021, USD Million
TABLE 20 North America Cancer Gene Therapy Market by Country, 2022 - 2028, USD Million
TABLE 21 US Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 22 US Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 23 US Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 24 US Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 25 US Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 26 US Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 27 Canada Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 28 Canada Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 29 Canada Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 30 Canada Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 31 Canada Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 32 Canada Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 33 Mexico Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 34 Mexico Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 35 Mexico Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 36 Mexico Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 37 Mexico Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 38 Mexico Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 39 Rest of North America Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 40 Rest of North America Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 41 Rest of North America Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 42 Rest of North America Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 43 Rest of North America Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 44 Rest of North America Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 45 Key Information – Novartis AG
TABLE 46 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 47 Key Information – Amgen, Inc.
TABLE 48 Key Information – Bristol Myers Squibb Company
TABLE 49 key Information – Karyopharm Therapeutics, Inc.
TABLE 50 Key Information – Gilead Sciences, Inc.
TABLE 51 Key information – Adaptimmune Limited
TABLE 52 Key Information – Genelux Corporation
TABLE 53 key information – Sarepta Therapeutics, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Novartis AG
FIG 3 Recent strategies and developments: Bristol Myers Squibb Company